Serial plasma concentrations of PYY and ghrelin during chemotherapy in children with acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 10, 2008, Pages 733-737

  Moschovi, Maria ^a   Trimis, Georgios ^a   Vounatsou, Maria ^b   Katsibardi, Katerina ^a   Margeli, Alexandra ^b   Dimitriadi, Filia ^a   Papassotiriou, Ioannis ^b   Chrousos, George ^a   Tzortzatou Stathopoulou, Fotini ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Acute lymphoblastic leukemia; Anorexia cachexia; Body mass index; Ghrelin; PYY

Indexed keywords

ANTINEOPLASTIC AGENT; GHRELIN; LACTATE DEHYDROGENASE; PEPTIDE YY; PEPTIDE HORMONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BODY MASS; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; BLOOD; CASE CONTROL STUDY; TIME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GHRELIN; HUMANS; PEPTIDE HORMONES; PEPTIDE YY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TIME FACTORS; TUMOR BURDEN;

EID: 58149216746     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318179a1d8     Document Type: Article

References (32)

1. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52:72-91.
2. McClement S. Cancer anorexia-cachexia syndrome: psychological effect on the patient and family. J Wound Ostomy Continence Nurs. 2005;32:264-268.
3. Perez-Tilve D, Nogueiras R, Mallo F, et al. Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance and metabolism. Endocrine. 2006;29:61-71.
4. Vrang N, Madsen AN, Tang-Christensen M, et al. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol. 2006;291:367-375.
5. Tovar SA, Seoane LM, Caminos JE, et al. Regulation of peptide YY levels by age, hormonal, and nutritional status. Obes Res. 2004; 12:1944-1950.
6. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89:71-84.
7. Schmidt PT, Degerblad M, Lindstrom E, et al. Circulating ghrelin levels after food intake during different phases of the migrating motor complex in man. Eur J Clin Invest. 2006;36:503-508.
8. Levin F, Edholm T, Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal weight. J Clin Endocrinol Metab. 2006;91:3296-3302.
9. Seoane LM, Al-Massadi O, Lage M, et al. Ghrelin: from a GH-secretagogue to the regulation of food intake, sleep and anxiety. Pediatr Endocrinol Rev. 2004;1(suppl 3):432-437.
10. Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care. 2004;7:427-434.
11. Argiles JM, Busquets S, Garcia-Martinez C, et al. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition. 2005;21:977-985.
12. Krohn K, Boczan C, Otto B, et al. Regulation of ghrelin is related to estimated insulin sensitivity in obese children. Int J Obes (London). 2006;30:1482-1487.
13. Druce MR, Neary NM, Small CJ, et al. Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes (London). 2006;30:293-296.
14. Laviano A, Meguid MM, Inui A, et al. Therapy insight: cancer anorexia-cachexia syndrome - when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2:158-165.
15. Tzortzatou-Stathopoulou F, Moschovi MA, Papadopoulou AL, et al. Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors? Eur J Haematol. 2005;75:361-369.
16. Tzortzatou-Stathopoulou F, Papadopoulou AL, Moschovi M, et al. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy. J Pediatr Hematol Oncol. 2001;23:591-597.
17. Van der Velden VH, Boeckx N, van Wering ER, et al. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents. 2004;18:146-154.
18. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003;9:774-778.
19. Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106:966-973.
20. Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90:2920-2926.
21. Whatmore AJ, Hall CM, Jones J, et al. Ghrelin concentrations in healthy children and adolescents. Clin Endocrinol. 2003;59:649-654.
22. Syrenicz A, Garanty-Bogacka B, Syrenicz M, et al. Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. Neuro Endocrinol Lett. 2006;27:453-458.
23. Foster-Schubert KE, Overduin J, Prudom CE, et al. Acyl and total ghrelin are suppressed strongly by ingested proteins, weakly by lipids, and biphasically by carbohydrates. J Clin Endocrinol Metab. 2008 [Epub ahead of print].
24. Moschovi M, Trimis G, Apostolakou F, et al. Serum lipid alterations in acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol. 2004;26:289-293.
25. Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;109:2221-2226.
26. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112:2986-2992.
27. Zhou J, Hegsted M, McCutcheon KL, et al. Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity (Silver Spring). 2006;14:683-689.
28. Chan JL, Stoyneva V, Kelesidis T, et al. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia. 2006;49:169-173.
29. Roth CL, Enriori PJ, Harz K, et al. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab. 2005;90:6386-6391.
30. Boey D, Lin S, Karl T, et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia. 2006;49:1360-1370.
31. Tseng WW, Liu CD. Peptide YY and cancer: current findings and potential clinical applications. Peptides. 2002;23:389-395.
32. Siahanidou T, Mandyla H, Vounatsou M, et al. Circulating peptide YY concentrations are higher in preterm than full-term infants and correlate negatively with body weight and positively with serum ghrelin concentrations. Clin Chem. 2005;51:2131-2137.